Leonard Schleifer (Photo by: Adam Jeffery/CNBC/NBCU Photo Bank via Getty Images)

Re­gen­eron inks $1B+ deal for glob­al rights to Sanofi-part­nered PD-1 Lib­tayo

Sanofi CEO Paul Hud­son made clear ear­li­er this year that his mis­sion to re­shape the com­pa­ny would in­volve some pipeline prun­ing. For the right price that ap­par­ent­ly in­cludes Lib­tayo, mere months ahead of an ex­pect­ed FDA de­ci­sion on lung can­cer.

Re­gen­eron is putting down a whop­ping $900 mil­lion up­front for the full rights to Lib­tayo, their part­nered PD-1 treat­ment that earned Re­gen­eron $306 mil­lion last year, up 13% from the year be­fore.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.